{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:28:45Z","timestamp":1761128925039},"reference-count":6,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,7,26]],"date-time":"2011-07-26T00:00:00Z","timestamp":1311638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2011,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This analysis evaluated the effects of deferasirox on liver iron concentration in moderate and heavily iron\u2010overloaded patients with \u03b2\u2010thalassaemia from the ESCALATOR trial (<jats:italic>n\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>231). Mean liver iron concentrations (LIC) decreased significantly from 21.1\u2003\u00b1\u20038.2 to 14.2\u2003\u00b1\u200312.1\u2003mg Fe\/g dry weight (dw) at 2\u2003yr (<jats:italic>P\u2003<\/jats:italic>&lt;\u20030.001) in patients with LIC \u22657\u2003mg Fe\/g dw at baseline; patients with LIC &lt;7\u2003mg Fe\/g dw maintained these levels over the treatment period. The proportion of patients with LIC &lt;7\u2003mg Fe\/g dw increased from 9.4% at core baseline to 39.3% by the end of year 2. The results showed that deferasirox enabled therapeutic goals to be achieved, by maintaining LIC in patients with LIC &lt;7\u2003mg Fe\/g dw at a mean dose of 22.4\u2003\u00b1\u20035.2\u2003mg\/kg\/d and significantly reducing LIC in patients with LIC \u22657\u2003mg Fe\/g dw at a mean dose of 25.7\u2003\u00b1\u20034.2\u2003mg\/kg\/d, along with a manageable safety profile.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2011.01661.x","type":"journal-article","created":{"date-parts":[[2011,6,11]],"date-time":"2011-06-11T14:31:30Z","timestamp":1307802690000},"page":"349-354","source":"Crossref","is-referenced-by-count":9,"title":["Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with \u03b2\u2010thalassaemia: results from the ESCALATOR study"],"prefix":"10.1111","volume":"87","author":[{"given":"Ali","family":"Taher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen S.","family":"Elalfy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kusai","family":"Al Zir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahina","family":"Daar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Al Jefri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dany","family":"Habr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Kriemler\u2010Krahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Roubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amal","family":"El\u2010Beshlawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,7,26]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.3.739"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01228.x"},{"key":"e_1_2_6_4_2","article-title":"Importance of optimal dosing 30 mg\/kg\/d during deferasirox treatment: 2.7\u2010yr follow\u2010up from the ESCALATOR study in patients with \u03b2\u2010thalassaemia","author":"Taher A","journal-title":"Eur J Haematol"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.eurheartj.a061916"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409013310903"},{"issue":"2","key":"e_1_2_6_7_2","article-title":"Efficacy and safety of deferasirox in patients with baseline liver iron concentration (LIC) <7 or >=7\u2003mg Fe\/g dw: results of EPIC liver magnetic resonance imaging (MRI) substudy","volume":"95","author":"Porter JB","year":"2010","journal-title":"Haematologica"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2011.01661.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2011.01661.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T21:31:22Z","timestamp":1697319082000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2011.01661.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,26]]},"references-count":6,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["10.1111\/j.1600-0609.2011.01661.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2011.01661.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,26]]}}}